Sunshine Biopharma Inc. (SBFM) Short-Term Debt to Equity

Sunshine Biopharma (SBFM) currently relies on the sale of generic drug copies for its cash flow, while growth potential is embedded in future tests of new antiviral compounds. However, the company faces threats from potential research failures and a shortage of internal funds. This price action chart with the 0.00 indicator confirms that quotes depend on patents, ignoring macroeconomic cycles and inflation.

The short-term debt-to-equity ratio measures the proportion of liabilities maturing within one year relative to shareholders' equity, determining liquidity risk and the degree of reliance on external financing. For Sunshine Biopharma (SBFM), where management focuses on attracting R&D investments, the historical trend of short-term loans to equity reflects the balance between financial stability and the aggressive development of biotechnological projects.